Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(0.79)
# 3,620
Out of 4,814 analysts
52
Total ratings
20%
Success rate
-15.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $14.92 | - | 2 | Apr 3, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $1.13 | - | 1 | Mar 18, 2025 | |
| MTSR Metsera | Initiates: Overweight | n/a | $17.55 | - | 1 | Feb 25, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $14.06 | - | 3 | Jan 21, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $4.77 | - | 6 | Jan 14, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $3.11 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $5.78 | +73.01% | 1 | Dec 17, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $301.73 | - | 4 | Nov 20, 2024 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $21.69 | +199.75% | 12 | Sep 23, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Overweight | n/a | $37.90 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $37.65 | - | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.79 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $38.32 | -37.37% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.51 | +17,828.29% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $0.47 | +2,897.86% | 1 | Mar 3, 2021 |
Travere Therapeutics
Apr 3, 2025
Reiterates: Overweight
Price Target: n/a
Current: $14.92
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.13
Upside: -
Metsera
Feb 25, 2025
Initiates: Overweight
Price Target: n/a
Current: $17.55
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $14.06
Upside: -
ORIC Pharmaceuticals
Jan 14, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.77
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.11
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $5.78
Upside: +73.01%
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $301.73
Upside: -
Structure Therapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: $65
Current: $21.69
Upside: +199.75%
MoonLake Immunotherapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $37.90
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $37.65
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.79
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $38.32
Upside: -37.37%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.51
Upside: +17,828.29%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $0.47
Upside: +2,897.86%